US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

While Teva’s innovative drug portfolio continues to thrive, generics, including biosimilars, are still the company’s bell cow as the sector’s worldwide sales of $2.54 billion accounted for ...

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...

The fine of €462.6 million ($503 million) is believed to be the largest imposed on a pharma company for breaking antitrust ...

European Union antitrust authorities fined Israel’s Teva Pharmaceuticals TEVA0.70%increase; green up pointing triangle 462.6 million euros ($502.3 million), saying the company abused its market ...

To do that, Teva conducted a “disparagement campaign” against Synthon, the only other company with an authorized drug in Europe containing glatiramer acetate, the commission said in a statement.

The EU Commission said Teva's actions may have prevented significant savings by countries across Europe, with other versions of the drug possibly 80% cheaper than Copaxone. Teva will have to pay a ...